# creating synergy



'The task of ensuring reliable and sustainable manufacturing of medicines and other health technologies is a complex undertaking that requires highly accountable and strategic partnerships. [...] The AUC's PMPA Business Plan, as well as its Roadmap on Shared Responsibility and Solidarity, provide excellent platforms around which international partners [...] can contribute'

<sup>1</sup>Commodities for better health in Africa - time to invest locally. Michel Sidibé, Li Yong and Margaret Chan. Bulletin of the World Health Organization 2014;92:387-387A - doi: http://dx.doi.org/10.2471/BLT.14.140566

#### FOR MORE INFORMATION PLEASE CONTACT:

Janet Byaruhanga
Health Officer
Social Affairs Department
African Union Commission

Roosvelt Street (Old Airport Area) PO. Box 3243, W21K19, Addis Ababa, Ethiopia Tel: (251) 11 551 77 00 E-mail: byaruhangaj@africa-union.org

**Alastair West** 

Senior Technical Advisor Business Investment and Technology Services Branch United Nations

Industrial Development Organization
Vienna International Centre

P.O. Box 300, 1400 Vienna, Austria Tel (+43) 1 26026 3882 E mail: a.west@unido.org



# PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA

### Business Plan

Developing competitive and sustainable pharmaceutical manufacturing industries in Africa able to respond to the continent's need for a secure and reliable supply of quality-assured, safe and efficacious medicines at affordable prices



© UNIDO 2015 All rights reserv

This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development Designations such as "developer," industrialized" or "developing" are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. Unless otherwise mentioned, all references to sums of money are given in United States dollars. Photos Owwshutterstock.com



African Union-Union Africaine União Africana- الاتحاد الأفريقي



Prepared as part of the AUC-UNIDO Partnership

# WHY? health & prosperity

Infectious and increasingly also non-communicable diseases pose a major threat to the health and prosperity of populations in Africa. The massive disease burden, including 75% of the world's HIV/AIDS cases and 90% of deaths resulting from malaria, could be alleviated substantially if high quality and affordable medicines were readily available to treat patients in need.

**75**%

of the world's HIV/AIDS case



deaths resultin from malaria 90%

## potential benefits

At the same time, there is growing recognition of the strategic importance of the pharmaceutical sector and the potential benefits that could be derived in terms of both health outcomes and economic growth if the continent's medicine requirements were increasingly satisfied by sustainable high quality local production.







## challenges

However, the pharmaceutical sector faces a multitude of hurdles impeding efforts to upgrade facilities and production practices towards international standards. Such challenges are often interrelated and include the need for large capital investments, access to technology and knowhow, robust regulatory capacity and an operating environment that helps to increase the industry's competitiveness.



# WHAT?

## a comprehensive package of solutions

The complex nature of the pharmaceutical sector requires a comprehensive response in terms of technical support. The Business Plan for the accelerated implementation of the PMPA therefore proposes a package of generic solutions that can be tailored to specific country-level and sub-regional contexts, addressing dimensions such as:

#### HUMAN RESOURCES

Strengthening and upgrading human resources



# HOW?

## joining forces & working together

Addressing such a diverse range of issues requires multiple partners to join forces and work together. The AUC has convened a consortium of partners and has invited UNIDO to coordinate its activities. The initiative has high-level support within the international community, as evidenced, for example, by a recent editorial in the WHO Bulletin co-authored by the heads of UNAIDS, UNIDO and WHO. They jointly call for the rapid, strategic development of pharmaceutical industries in Africa through implementing the PMPA BP approach.

### Success

The success of this collaborative approach will depend on a number of factors, including a legal framework with clearly defined governance and reporting structures, a detailed work plan, measures for monitoring and evaluation, and availability of central resources.

#### resources

The resources required for full implementation of the Business Plan over a five year period have been estimated to amount to approximately US\$ 54 million. There is a need for initial seed funding to put in place appropriate coordination capacity.

At national level, the consortium partners are already learning to work together in Ghana where early implementation of the Business Plan is being conducted following an official request by President Mahama in 2013. They will also support the implementation of the National Strategy and Action Plan for Development of Pharmaceutical Manufacturing in Ethiopia. The partnership will also seek to create synergies with complementary initiatives and ambitions that have been developed at the level of the Regional Economic Communities (REC), such as the ECOWAS Regional Pharmaceutical Plan (ERPP).